Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Meta-analyses of clinical trials comparing CSII with traditional insulin injections usually show a small, but significant advantage of CSII with respect to HbA1c and risk of severe hypoglycemia. On the other hand, CSII is associated with a small, but relevant risk of ketoacidosis, mainly due to malfunction of insulin pump and/or catheter occlusion. During last time, the technology of insulin pumps and infusion sets has improved as the profound evolution in type and schemes with traditional insulin injections. Aim of the present study is to update previous meta-analyses comparing CSII with traditional insulin injections in subjects with type 1 diabetes. Specific subgroup analyses were designed for assessing the effects of CSII in comparison with basal-bolus MDI, with short-acting analogues as bolus and long-acting analogues as basal insulin. In addition, an exploratory analysis was performed to verify the effect of CSII in insulin-naïve patients with type 1 diabetes. The present analysis includes all randomized clinical trials comparing CSII with traditional injections in type 1 diabetes, with a duration of at least 12 weeks. Animal studies were excluded, whereas no language or date restriction was imposed. If duplicate publications of a single trial were present, the paper containing more adequate information was considered as principal publication. In trials comparing CSII with basal-bolus MDI, performed before the introduction of rapid-acting analogues, regular human insulin was used for CSII, and as prandial insulin in control groups. CSII was associated with a significant reduction of A1c, in comparison with MDI, irrespective of the use of either human insulin or rapid-acting analogues. However, in trials with rapid-acting analogue the advantage of CSII was significantly smaller than in trials with regular human insulin (HbA1c difference: - 0.29[- 0.46; - 0.13] vs - 1.93[- 1.84; - 0.42]%; p = 0.02). Different rapid-acting analogues provided similar results (HbA1c reduction vs MDI: - 0.25 [- 0.48; - 0.02]%, p = 0.03, and - 0.29 [- 0.49; - 0.09]%, p = 0.005, for lispro and aspart, respectively). In addition, in trials comparing CSII with basal-bolus MDI, CSII reduced HbA1c to a similar extent irrespective of the use of either NPH or long-acting analogues as basal insulin in the control groups (HbA1c reduction vs MDI: - 0.31 [- 0.55; - 0.06]%, p = 0.01, and - 0.20 [- 0.38; - 0.03]%, p = 0.02, for NPH and long-acting analogues, respectively. With respect to severe hypoglycemia, CSII did not produce a significant reduction of risk in comparison with traditional insulin injections. Conversely, CSII was associated with a significant increase in the incidence of reported diabetic ketoacidosis (DKA). Notably, the increased risk of DKA was significant in trials comparing CSII with conventional insulin therapy, whereas only a nonsignificant trend toward an increased risk was observed in comparisons with basal-bolus MDI. Only two trials comparing CSII with basal-bolus MDI, both using rapid-acting analogues, were performed on insulin-naïve type 1 diabetic patients. When those two trials were analyzed separately, CSII did not produce any relevant effect on HbA1c (difference from control: - 0.10[- 0.38; + 0.17]%; p = 0.46). No meta-analysis could be performed on either severe hypoglycemia or DKA, which were not reported by one of the two trials. CSII seems to produce a small improvement in HbA1c in patients with type 1 diabetes inadequately controlled with MDI. This apparent effect, which could be partly due to publication bias, is smaller when MDI is properly performed using basal-bolus schemes with short-acting insulin analogues. Other outcomes different from HbA1c (such as quality of life) could be relevant for the choice of CSII instead of MDI. In addition, further studies are needed to better define the profile of patients who could benefit most from CSII.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of SAP therapy has been shown to improve not just A1C or hypoglycemia but also glycemic variability and albuminuria1185–1187 when compared with MDI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1185]
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Pickup, J. C., & Sutton, A. J. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02486.x · Cited by 617
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Pickup, J., Mattock, M., & Kerry, S. (2002) · BMJ · doi:10.1136/bmj.324.7339.705 · Cited by 483
Misso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406
Jeitler, K., Horvath, K., Berghold, A., Gratzer, T. W., Neeser, K., Pieber, T. R., & Siebenhofer, A. (2008) · Diabetologia · doi:10.1007/s00125-008-0974-3 · Cited by 375
Cummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14110 · Cited by 335
Insulin-pump therapy for type 1 diabetes mellitus
Pickup, J. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1113948 · Cited by 270
Research works printed but not linked: 1
- Jacobsen IB, Henriksen JE, Hother-Nielsen O, Vach W, Beck-Nielsen H (2009) Evidence-based insulin treatment in type 1 diabetes mellitus. Diabetes Res ClinPract 86(1):1–10 · DOI
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Dhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0165-1 · Cited by 461
Ren, C., Zhong, D., Qi, Y., Liu, C., Liu, X., Chen, S., Yan, S., & Zhou, M. (2023) · ACS Nano · doi:10.1021/acsnano.3c04897 · Cited by 115
Domingo‐Lopez, D. A., Lattanzi, G., Schreiber, L. H. J., Wallace, E. J., Wylie, R., O’Sullivan, J., Dolan, E. B., & Duffy, G. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114280 · Cited by 125
Dicembrini, I., Cosentino, C., Monami, M., Mannucci, E., & Pala, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01589-3 · Cited by 106
Self-citationDiabetic Ketoacidosis in Children and Adolescents; Diagnostic and Therapeutic Pitfalls
Kostopoulou, E., Sinopidis, X., Fouzas, S., Gkentzi, D., Dassios, T. G., Roupakias, S., & Dimitriou, G. (2023) · Diagnostics · doi:10.3390/diagnostics13152602 · Cited by 90
“In any case, the use of continuous glucose monitoring (CGM), as well as close monitoring of blood ketones, administration of correction boluses through insulin pens in the case of persisting hyperglycaemia, and frequent reinforcement of DKA prevention education, are some of the necessary and effective measures that sh…”
BackgroundBoscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 80
Prigge, R., McKnight, J. A., Wild, S. H., Haynes, A., Jones, T. W., Davis, E. A., Rami-Merhar, B. M., Fritsch, M., Prchla, C., Lavens, A., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14766 · Cited by 73
Saunders, A., Messer, L. H., & Forlenza, G. P. (2019) · Expert Review of Medical Devices · doi:10.1080/17434440.2019.1670639 · Cited by 62
“comfort of injections for the patient [5].”
Gandhi, K. K., Ebekozien, O. A., Noor, N., McDonough, R., Hsieh, S., Miyazaki, B., Dei-Tutu, S. A., Golden, L., Desimone, M. E., Hardison, H., et al. (2023) · Clinical Diabetes · doi:10.2337/cd23-0055 · Cited by 51
An overview of advancements in closed-loop artificial pancreas system
Dermawan, D., & Purbayanto, M. A. K. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11648 · Cited by 50
“Besides, insulin pumps can provide multiple doses a day without the discomfort caused by injections to individuals with T1D [8].”
BackgroundSandig, D., Grimsmann, J., Reinauer, C., Melmer, A., Zimny, S., Müller-Korbsch, M., Forestier, N., Zeyfang, A., Bramlage, P., Danne, T., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0019 · Cited by 43
“25,26 This refers to a recent meta-analysis 27 of randomized clinical trials comparing CSII versus MDI in T1D pointing out the advantage of CSII being significantly smaller when rapid-acting analogs were used instead of human insulin.”
Phillip, M., Mathieu, C., Lind, M., Araki, E., di Bartolo, P., Bergenstal, R., Heller, S., Hansen, L., Scheerer, M. F., Thoren, F., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14248 · Cited by 41
“This was also found in a meta-analysis of randomized controlled trials, where DKA was generally more common in those having CSII as the mode of insulin administration, regardless of the use of SGLT-2 inhibitors.(32) Hence, the risk ratio is not higher in users of CSII for dapagliflozin versus placebo, but may only ref…”
ResultMughal, I. S., Patané, L., & Caponetto, R. (2024) · Annual Reviews in Control · doi:10.1016/j.arcontrol.2024.100937 · Cited by 46
Shaikh, A. M. A., Zahrani, A. M. A., Qari, Y. H., Alnasr, A. A. A., Alhawsawi, W., Alshehri, K., & Alshaikh, S. A. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420959077 · Cited by 44
PAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 46
Current Management of Glycemia in Children with Type 1 Diabetes Mellitus
Sperling, M. A., & Laffel, L. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2112175 · Cited by 43
Lyons, S. K., Ebekozien, O. A., Garrity, A. N., BUCKINGHAM, D. A., Odugbesan, O., Thomas, S. E., Rioles, N. A., Gallagher, K., Sonabend, R., Lorincz, I. S., et al. (2021) · Clinical Diabetes · doi:10.2337/cd21-0027 · Cited by 39
“, intermediate and long-acting) analog insulins (3).”
Antich-Isern, P., Caro-Barri, J., & Aparicio-Blanco, J. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120992 · Cited by 44
Thomas, M., Harjutsalo, V., Feodoroff, M., Forsblom, C., Gordin, D., & Groop, P.-H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz003 · Cited by 30
Dhatariya, K., Bergenstal, R. M., Al‐Sofiani, M. E., Albanese-O’Neill, A., Battelino, T., Close, K. L., Block, C. E. M. D., Dutta, S., Galindo, R. J., GhavamiNejad, A., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00331-6 · Cited by 33
Tomulić, K. L., Matko, L., Verbić, A., Milardović, A., Severinski, S., Kolić, I., Dekanić, K. B., Šerifi, S., & Ahel, I. B. (2022) · Medicina · doi:10.3390/medicina58050638 · Cited by 30
“A recent meta-analysis shows a significant increase in the incidence of reported DKA in patients with continuous subcutaneous insulin infusion, mainly due to malfunction of insulin pump or catheter infusion [24].”
MethodA clinical review of the t:slim X2 insulin pump
Berget, C., Lange, S. L., Messer, L. H., & Forlenza, G. P. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1814734 · Cited by 27
Serné, E. H., Roze, S., Buompensiere, M. I., Valentine, W. J., de Portu, S., & de Valk, H. W. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02058-9 · Cited by 27
Horii, T., Oikawa, Y., Atsuda, K., & Shimada, A. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13506 · Cited by 23
Stamati, A., Karagiannis, T., Τσάπας, Α., & Christoforidis, A. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110144 · Cited by 23
Dicembrini, I., Pala, L., Caliri, M., Minardi, S., Cosentino, C., Monami, M., & Mannucci, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14028 · Cited by 22
“Available randomized trials in type 1 diabetes show that CSII produces a small, but significant reduction in glycated haemoglobin (HbA1c) in comparison with multiple daily injections (MDI), without increasing the risk of severe hypoglycaemia.(1) CSII is also associated with an increased risk of ketoacidosis in compari…”
BackgroundSelf-citationThomas, M. G., Avari, P., Godsland, I. F., Lett, A. M., Reddy, M., & Oliver, N. S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14498 · Cited by 23
Use and Trends of Diabetes Self-Management Technologies: A Correlation-Based Study
Fontecha, J., Gónzalez, I., Barragán, A., & Lim, T. (2022) · Journal of Diabetes Research · doi:10.1155/2022/5962001 · Cited by 22
“Although many works are focused on determining the strong and weak points of treatment regimens such as Multiple Daily Injections (MDI) and Continuous Subcutaneous Insulin Infusion (CSII) [7, 8], the use of CGM systems provides benefits in both cases [9].”
BackgroundChoe, J., Won, S., Choe, Y., Park, S. H., Lee, Y. J., Lee, J. E., Lee, Y. A., Lim, H. H., Yoo, J. H., Lee, S. Y., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0274 · Cited by 19
“In adult T1D patients, mean HbA1c levels were 0.3%– 0.6% lower with CSII in comparison with MDI, 33–36 and the reduction in HbA1c was also observed in patients with poor control of diabetes with MDI after being shifted to CSII.”
InfluentialHu, S., Yang, H., Chen, Z., Leng, X., Li, C., Qiao, L., Lv, W., & Tang, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.604028 · Cited by 19
Guo, K., Li, J., Liyin, Z., Ye, J., Fan, L., Ding, Z., Qin, Z., Li, X., Lin, Y., & Zhou, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.990281 · Cited by 17
Haughton, S., Riley, D. R. J., Berry, S. A., Arshad, M. F., Eleftheriadou, A., Anson, M., Yap, Y. W., Cuthbertson, D. J., Malik, R. A., Azmi, S., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16455 · Cited by 17
“12,13 Our data demonstrate a clinically meaningful improvement in glycaemia in both the insulin pump and the MDI groups.”
An Intelligent Model-Based Effective Approach for Glycemic Control in Type-1 Diabetes
Khaqan, A., Nauman, A., Shuja, S., Khurshaid, T., & Kim, K.-C. (2022) · Sensors · doi:10.3390/s22207773 · Cited by 14
“In [6], the authors reviewed and compared the preceding analysis and performance with the existing CSII pumps in the type 1 diabetic patients.”
Albaladejo, L., Périnet-Marquet, P., Buis, C., Lablanche, S., Iceta, S., Arnol, N., Logerot, S., Borel, J., & Betry, C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110630 · Cited by 14
van Wilpe, R., Hulst, A. H., Siegelaar, S. E., DeVries, J. H., Preckel, B., & Hermanides, J. (2022) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2022.111012 · Cited by 16
Insulin requirements during pregnancy in women with type 1 diabetes treated with insulin pump
Dori‐Dayan, N., Cukierman‐Yaffe, T., Zemet, R., Cohen, O., Levi, K., Mazaki‐Tovi, S., & Yoeli‐Ullman, R. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3771 · Cited by 13
STOUGAARD, E. B., Amadid, H., Søndergaard, E., Carstensen, B., Jørgensen, M. E., Nørgaard, K., Rossing, P. R., Persson, F., & Vistisen, D. (2023) · Diabetes Care · doi:10.2337/dc23-0475 · Cited by 14
A Nutritional Approach to Optimizing Pump Therapy in Type 1 Diabetes Mellitus
Gitsi, E., Livadas, S., Angelopoulos, N., Paparodis, R. D., Raftopoulou, M., & Argyrakopoulou, G. (2023) · Nutrients · doi:10.3390/nu15234897 · Cited by 13
Insulin Pump Use and Diabetic Ketoacidosis Risk in Type 1 Diabetes: Secular Trends over Four Decades
BUDHRAM, D. R., Bapat, P., BAKHSH, A. M. K., Abuabat, M. I., Verhoeff, N. J., Mumford, D., Cheema, W., Orszag, A., JAIN, A., Cherney, D. Z. I., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0272 · Cited by 12
Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes
Block, C. E. M. D., Cauwenberghe, J. V., Bochanen, N., & Dirinck, E. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14713 · Cited by 13
Pitocco, D., Laurenzi, A., Tomaselli, L. G., Assaloni, R., Consoli, A., Bartolo, P. D., Guardasole, V., Lombardo, F., Maffeis, C., Rossi, A., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.003 · Cited by 13
Increasing Use of Diabetes Devices: What Do Health Care Professionals Need?
Messer, L. H., Vigers, T., Aktürk, H. K., Forlenza, G. P., Huss, K. B., KARAMI, A. J., MALECHA, E., Oser, S. M., Polsky, S., Pyle, L., et al. (2023) · Clinical Diabetes · doi:10.2337/cd22-0092 · Cited by 11
Szadkowska, A., Baranowska‐Jaźwiecka, A., Michalak, A., Jarosz-Chobot, P. A., Myśliwiec, M., Głowińska‐Olszewska, B., Szypowska, A., Nazim, J., Mazur, A., Szalecki, M., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13250 · Cited by 15
Yu, J. M., Wang, H., Zhu, M., & Xu, J. (2024) · Health and Quality of Life Outcomes · doi:10.1186/s12955-024-02263-w · Cited by 9
“While a meta-analysis showed that effect of CSII over MDI on HbA 1C was − 0.42[ − 0.66; − 0.18]% in those enrolling only adult T1DM patients [8].”
MethodInfluentialLu, J., Vogrin, S., McAuley, S. A., Lee, M. H., Paldus, B., Bach, L. A., Burt, M. G., Clarke, P., Cohen, N. D., Colman, P. G., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109000 · Cited by 10
Estock, J. L., Codario, R. A., Keddem, S., Zupa, M. F., Rodriguez, K. L., & DiNardo, M. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0498 · Cited by 10
Park, J., Park, N., Han, S., Lee, Y., Kim, G., Jin, S., Lee, W. J., & Kim, J. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0299 · Cited by 8
“CSII increases patient satisfaction and is effective for glycemic control, prevention of hypoglycemia, and decreasing cardiovascular mortality compared to MDI [1-4].”
BackgroundInfluentialAlnaim, N., Ghadeer, H. A. A., Albunyan, A., Almulhem, A., Alsaleh, Y., AlHelal, M., Almugaizel, I., Alhashim, Z., Alhamrani, A. M., & Bosrour, Z. A. A. (2024) · Cureus · doi:10.7759/cureus.54123 · Cited by 8
“Although there are several ways to make insulin administration easier for families, such as insulin ports and jets, the majority of clinical centers still treat patients with multiple daily injections (MDI) of insulin analogs as the standard of care [10].”
BackgroundAlmazrouei, R. A., Sharma, C., Afandi, B. O., Aldahmani, K. M., Aburawi, E. H., Beshyah, S., ElGhazali, G. E., Yafei, Z. A., Al‐Rifai, R. H., & Alkaabi, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264545 · Cited by 7
“In contrast, only a non-significant trend toward increased risk was observed compared with basal-bolus MDI [30].”
Resultde Jongh, D., Thom, R. L., Cronin, A. J., Bunnik, E. M., & Massey, E. K. (2023) · Transplant International · doi:10.3389/ti.2023.11705 · Cited by 7
Li, W. (2020) · Preprints.org · doi:10.20944/preprints202007.0552.v1 · Cited by 8
“Pharmacologically, due to its significantly reduced self-association, insulin lispro offers faster subcutaneous absorption, and begins to exert its effects earlier than its wild-type counterpart [16, 17, 18, 19, 20, 21, 22, 23].”
Li, Y., Shao, Z., Zhu, Y., Chen, D., & Zhu, J. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13536 · Cited by 7
García, M. I., Céspedes, C., Durán, P., Forero, C., & Mauricio Coll, B. (2023) · Biomédica · doi:10.7705/biomedica.6675 · Cited by 11
“(17), quienes llevaron a cabo un metaanálisis para comparar la bomba de insulina frente a las inyecciones de insulina tradicionales (1 a 2 inyecciones diarias con esquemas de insulina cristalina y NPH).”
BackgroundSwaminathan, K. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_324_22 · Cited by 6
“Continuous subcutaneous insulin infusion (CSII) is a very effective way of insulin delivery in highly selected patients with Type 1 diabetes, with accumulating evidence for the role of CSII in improving quality of life,[2] reducing clinically relevant recurrent and severe hypoglycaemias,[3] significant reductions in g…”
BackgroundDually crosslinked degradable polyionic micelles for sustained glucose-responsive insulin release
Ma, Y., Xing, Y., Han, F., Xu, J., Qian, H., Chen, W., & Huang, D. (2024) · Biomaterials Science · doi:10.1039/d4bm00314d · Cited by 6
Intensive Insulin Therapy (Basal-Bolus)
Chico, A. I., & Corcoy, R. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001152 · Cited by 6
McKee, A. M., Al-Hammadi, N. J., & Hinyard, L. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.001 · Cited by 5
Precipitating Factors and Symptoms in Patients with Diabetic Ketoacidosis
Dragila, Ž. (2023) · Acta Clinica Croatica · doi:10.20471/acc.2023.62.01.08 · Cited by 10
“However, in the 2019 meta-analysis, no significantly increased risk of DKA was found compared to multiple daily insulin injections 33 .”
BackgroundKong, Y. W., Yuan, C. Y., Kiburg, K., Brown, K., Trawley, S. L., Partovi, A., ROEM, K. L., Pham, C. T., Harrison, N., Fourlanos, S., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae088 · Cited by 7
Vlahou, C. H., Petrovski, G., Korayem, M., Khalaf, F. A., Awwa, A. E., Mahmood, O. M., & Azeem, M. W. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13200 · Cited by 5
Insulin Pump–related Inpatient Admissions in a National Sample of Youth With Type 1 Diabetes
Everett, E. M., Copeland, T. P., Moin, T., & Wisk, L. E. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac047 · Cited by 6
Ståhl, F. L., Hellman, J., & Ekelund, C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251414976 · Cited by 4
Kramer, G., Kloos, C., Müller, U., Wolf, G., & Kuniß, N. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00700-0 · Cited by 4
Noshad, E., Nozari, H. A., & Castaldi, P. (2025) · Journal of Control and Decision · doi:10.1080/23307706.2025.2504687 · Cited by 3
Barnard-Kelly, K. D., Thienel, F., Mader, J. K., Oliver, N. S., Franek, E., Vesper, I., DAGENBACH, N., Vogt, G., ETTER, T. J., & Künsting, T. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241234055 · Cited by 3
Wang, Y., Gao, W., & Wang, X. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i18.3378 · Cited by 3
“Clinical research results have shown that compared to subcutaneous injection of insulin, the use of insulin pumping can more effectively and stably control the blood glucose levels of patients with diabetes[13-15].”
Treatment and long-term follow-up of patients diagnosed with type 1 diabetes mellitus before age 5
Ata, A., Er, E., Evin, F., Işıklar, H., Abdullayev, N., Demir, G., Özen, S., Altınok, Y. A., Darcan, Ş., & Gökşen, D. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0205 · Cited by 4
Kong, Y. W., Yuan, C. Y., Kiburg, K., Brown, K., Trawley, S. L., Partovi, A., ROEM, K. L., Harrison, N., Fourlanos, S., Ekinci, E. I., et al. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01400-4 · Cited by 3
“Continuous subcutaneous insulin infusion or insulin pump therapy (IPT) can improve glycaemic management and the quality of life of people living with type 1 diabetes (T1D) compared with multiple daily injections (MDI) [1–3].”
BackgroundWang, W. T., & Loh, W. J. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000940 · Cited by 2
Ghaur, S. Y., Grinderslev, P. B., Leth‐Møller, M., Ovesen, P., Fuglsang, J., Fisker, S., McIntyre, D. H., & Kampmann, U. (2024) · Reproductive Medicine · doi:10.3390/reprodmed5010002 · Cited by 2
“Administering insulin by pump has for a long time been perceived as the best way to mimic physiological blood glucose concentrations and advantages with respect to HbA1c, and the risk of severe hypoglycemia has been proven when compared to multiple daily injections [22].”
BackgroundDurmanova, A., Slyamova, G., Rakhimzhanova, M., Gusmanov, A., Zhakanova, G., Abduakhassova, G., Issabayeva, A., Nurgaliyeva, A., Alzhaxina, A., Umerzakova, A., et al. (2024) · Electronic Journal of General Medicine · doi:10.29333/ejgm/14403 · Cited by 4
“Many studies indicate that CSII outperforms MDI in metabolic control because MDI is unable to adapt therapy to immediate changes in blood glucose [13, 15, 16].”
BackgroundMethodInfluentialThe use of TruCare III insulin pump in patients with type 1 diabetes mellitus
Алексеевич, Б. И., & Александровна, Д. А. (2024) · Problems of Endocrinology · doi:10.14341/probl13516 · Cited by 2
Machálková, L., Reiterová, E., Bartoníčková, D., & Durďáková, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112265 · Cited by 2
McKee, A. M., Albert, S. G., Al-Hammadi, N. J., & Hinyard, L. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.252 · Cited by 2
Diabetes Mellitus type 2: Management and follow up in Primary Health Care Center
Alkinani, A. A., Alkhrizi, I. M., Alkathiri, S. H., Alzubaidi, H. L. A., Alghanmi, A. A., Alghanmi, A. M., Alnashri, I. A., & Alruwaili Amal Muhaysin, B. (2021) · Archives of Pharmacy Practice · doi:10.51847/mvmt9sdifp · Cited by 4
Alissa, N., Alhumaidi, S., Alzaid, S., Aldibasi, O. S., Alfaraidi, H., & Almutair, A. (2024) · Pediatric Diabetes · doi:10.1155/2024/5529674 · Cited by 1
Izquierdo, V., Pazos-Couselo, M., González-Rodríguez, M., Martinez‐Santos, A., Andújar-Plata, P., Díaz-Trastoy, O., Fernández‐Pombo, A., Sigüeiro-Paulos, S., & Rodríguez‐González, R. (2024) · Health Education Research · doi:10.1093/her/cyae030 · Cited by 1
Objetivos del tratamiento de la diabetes mellitus tipo 1
Cebada, A. B., da Silva, J. K. H., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.002 · Cited by 2
Vitale, R. J., TINSLEY, L. J., Volkening, L. K., & Laffel, L. M. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0574 · Cited by 1
“21 The reduced use of insulin pumps among people with EF challenges may be a mediator of the association between EF challenges and higher A1c in adolescents with type 1 diabetes.”
InfluentialRateb, R. M., Salah, A., Kertam, A., Ashmawi, Y. A. Y., Mahmoud, N. H., Afifi, E., Bayoumi, A., Allam, S., & Rakab, M. S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01906-2 · Cited by 1
“The cumulative Z-curve (blue full line) passed both Superiority boundary and RIS sample line which suggest that the cumulative evidence is sufficient to conclude that Control IQ is superior to control group with the existing evidence insulin therapy group [35].”
Sakane, N., Kato, K., Hata, S., Nishimura, E., Araki, R., Kouyama, K., Hatao, M., Matoba, Y., Matsushita, Y., Domichi, M., et al. (2025) · Diabetology International · doi:10.1007/s13340-025-00846-6 · Cited by 1
“With respect to severe hypoglycemia, meta-analysis by Pala et al. (2019) showed that CSII did not produce a significant reduction of risk in comparison with traditional insulin injections.”
Nouvelles technologies : quelles innovations dans la prise en charge du diabète de l’enfant ?
Atger, L., Garcin, L., & Gérard, M. (2020) · Perfectionnement en Pédiatrie · doi:10.1016/j.perped.2020.07.008 · Cited by 1
Real-World Analysis of Therapeutic Outcome in Type 1 Diabetes Mellitus at a Tertiary Care Center
Kietaibl, A.-T., Riedl, M., & Bozkurt, L. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0267 · Cited by 2
“According to a recently published meta-analysis, there may be a decrease in statistically significant results between CSII and MDI once rapidacting analogues are applied [15].”
An Ethical Perspective on the Social Value of Cell-Based Technologies in Type 1 Diabetes
de Jongh, D., & Bunnik, E. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_19 · Cited by 1
Mathiesen, E. R., Alibegovic, A. C., Anil, G., Dunne, F., Halasa, T., Ivanišević, M., McCance, D. R., Nordsborg, R. B., Damm, P., & the EVOLVE study group (2024) · Diabetic Medicine · doi:10.1111/dme.15411 · Cited by 2
“22 A secondary analysis of data from the DPR 16 showed that use of CSII was not associated with a lower risk of congenital malformations, despite improved glycaemic control in early pregnancy.”
Managing Type 1 Diabetes in an Inpatient Child Psychiatric Care Setting
Olinger, A. L., Sachdeva, S., Manzardo, A. M., & Cain, S. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0008 · Cited by 1
Euglycemic Diabetic Ketoacidosis in a Pregnant Patient on Insulin Pump Therapy
Yasin, H., Ross, J. D., Turner, J., & Dagogo-Jack, S. E. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.10.004 · Cited by 1
Pujante, P., Delgado, E., Lambert, C., Rodríguez, M. M., Urbon, L., Maldonado, A., García, S., Serrallonga, N. B., Avino, L., Palomar, J. M. R., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251363452 · Cited by 1
“13 On one hand, CSII has transformed insulin administration, 14 reducing hypoglycemia and improving both glycemic con-trol 15 and QoL.”
Álvarez, S. O. (2019) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14103.2019.581140
Tecnologia, diabete e gravidanza
Bonomo, M. A., Feig, D. S., Pintaudi, B., Mion, E., & Bertuzzi, F. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00858-9
“associata al CGM, meta-analisi recenti hanno mostrato un vantaggio sui livelli di HbA1c modesto, ma statisticamente significativo [1], anche in confronto a schemi di MDI che utilizzano esclusivamente analoghi rapidi e long-acting [2].”
BackgroundDevelopment of a Simplified Insulin Pump Interface for Improved User Interaction
Harper, A., Wilson, W., & Choi, Y. M. (2021) · Lecture notes in networks and systems · doi:10.1007/978-3-030-80829-7_23
Evolución de los sistemas de infusión de insulina: el camino al páncreas artificial
de la Maza-Viadero, M. E. S., Almeda-Valdés, P., & Faradji-Hazan, R. N. (2021) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m21000015 · Cited by 1
(2021) · Elsevier eBooks · doi:10.1016/b978-3-437-21421-9.00026-5
La sostituzione delle beta-cellule: indicazioni al trapianto di pancreas nel diabete
Giusti, M. A., Cintorino, D., Ricotta, C., Caccamo, C., Salis, P., Gruttadauria, S., & Mattina, A. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01125-1
“Numerosi sono i progressi nella gestione terapeutica del DM che hanno contribuito a cambiare la qualità e la prospettiva di vita dei pazienti: la terapia insulinica mediante micro-infusore (Continuous Subcutaneous Insulin Infusion, CSII) supportato dai sistemi di monitoraggio flash o continui del glucosio permette il…”
BackgroundYarı-biyonik İnsan: Yapay Kalp ve Yapay Pankreas Taşıyan Hastada Beslenme Tedavisi ve İzlemi
Şahiner, E., Yilmaz, M. T., & Kızıl, M. (2023) · Journal of Nutrition and Dietetics · doi:10.33076/2023.bdd.1778
New Technologies for Insulin Administration
Forde, H. E., & Choudhary, P. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch33
CONTROL OF TYPE 1 DIABETES IN CHILDREN USING AN INSULIN PUMP: THE ЕXPERIENCE OF ODESA DOCTORS
Velychko, V. I., Lahoda, D. O., Pencho, G. O., & Bazhora, Y. I. (2023) · doi:10.32782/2226-2008-2023-4-10
Nováková, M., Benešová, K., Jarkovský, J., Dušek, L., Holmerová, I., & Kvapil, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.065
Semenova, J. F., Serebrov, K. I., Koroleva, E. A., & Klimontov, V. V. (2024) · International Multi-Conference on Engineering, Computer and Information Sciences (SIBIRCON) · doi:10.1109/sibircon63777.2024.10758522
Metadata
- Authors
- Pala, L., Dicembrini, I., & Mannucci, E.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Pala, Laura
- Venue
- Acta Diabetologica
- Published
- 2019-04-03
- Volume
- 56
- Issue
- 9
- Pages
- 973-980
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2925696740
- Cited by
- 112
- References
- 22
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 22 · 2023: 17 · 2022: 18 · 2021: 20 · 2020: 11 · 2019: 3
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- insulin pump therapy, type 1 diabetes, multiple daily insulin injections, rapid-acting insulin analogs, HbA1c, glycemic control, hypoglycemia, diabetic ketoacidosis, insulin-naive patients, insulin lispro, regular insulin
- MeSH terms
- Diabetes Mellitus, Type 1, Drug Administration Schedule, Drug Combinations, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Male, Quality of Life, Randomized Controlled Trials as Topic, Diabetic Ketoacidosis, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.